Skip Nav Destination
Issues
February 2024
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
ISSN 2235-1795
EISSN 1664-5553
In this Issue
Liver Cancer 2024, Vol. 13, No. 1
Editorial
Review Article
Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management
Liangtao Ye; Julia S. Schneider; Najib Ben Khaled; Peter Schirmacher; Carolin Seifert; Lea Frey; Yulong He; Andreas Geier; Enrico N. De Toni; Changhua Zhang; Florian P. Reiter
Liver Cancer (2024) 13 (1): 6–28.
https://doi.org/10.1159/000530700
Research Article
Radiologic Patterns Determine the Outcomes of Initial and Subsequent Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma
Ya-Wen Hung; I-Cheng Lee; Chen-Ta Chi; Rheun-Chuan Lee; Chien-An Liu; Nai-Chi Chiu; Hsuen-En Hwang; Yee Chao; Ming-Chih Hou; Yi-Hsiang Huang
Liver Cancer (2024) 13 (1): 29–40.
https://doi.org/10.1159/000530950
HBV DNA Integration into Telomerase or MLL4 Genes and TERT Promoter Point Mutation as Three Independent Signatures in Subgrouping HBV-Related HCC with Distinct Features
Chiao-Ling Li; Chia-Lang Hsu; You-Yu Lin; Ming-Chih Ho; Hu; Chi-Ling Chen; Tung-Ching Ho; Yung-Feng Lin; Shih-Feng Tsai; Sheng-Tai Tzeng; Chin-Fang Huang; Ya-Chun Wang; Shiou-Hwei Yeh; Pei-Jer Chen
Liver Cancer (2024) 13 (1): 41–55.
https://doi.org/10.1159/000530699
Incidence of Hyper Progressive Disease in Combination Immunotherapy and Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Monotherapy for Unresectable Hepatocellular Carcinoma
Tomoko Aoki; Masatoshi Kudo; Kazuomi Ueshima; Masahiro Morita; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Masakatsu Tsurusaki; Naoshi Nishida
Liver Cancer (2024) 13 (1): 56–69.
https://doi.org/10.1159/000531024
Multimodal Integrative Genomics and Pathology Analyses in Neoadjuvant Nivolumab Treatment for Intermediate and Locally Advanced Hepatocellular Carcinoma
Tan-To Cheung; Daniel Wai-Hung Ho; Shirley Xueying Lyu; Qingyang Zhang; Yu-Man Tsui; Tiffany Ching-Yun Yu; Karen Man-Fong Sze; Joyce Man-Fong Lee; Vince Wing-hang Lau; Edward Yin-Lun Chu; Simon Hing-Yin Tsang; Wong-Hoi She; Roland Ching-Yu Leung; Thomas Chung-Cheung Yau; Irene Oi-Lin Ng
Liver Cancer (2024) 13 (1): 70–88.
https://doi.org/10.1159/000531176
Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma
Young Shin Song; Hannah Yang; Beodeul Kang; Jaekyung Cheon; Ilhwan Kim; Hyeyeong Kim; Won Suk Lee; Yun Beom Sang; Sanghoon Jung; Ho Yeong Lim; Vincent E. Gaillard; Chan Kim; Hong Jae Chon
Liver Cancer (2024) 13 (1): 89–98.
https://doi.org/10.1159/000531182
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial
Masatoshi Kudo; Kazuomi Ueshima; Issei Saeki; Toru Ishikawa; Yoshitaka Inaba; Naoki Morimoto; Hiroshi Aikata; Nobukazu Tanabe; Yoshiyuki Wada; Yasuteru Kondo; Masahiro Tsuda; Kazuhiko Nakao; Takanori Ito; Tetsuya Hosaka; Yusuke Kawamura; Teiji Kuzuya; Shunsuke Nojiri; Chikara Ogawa; Hironori Koga; Keisuke Hino; Masafumi Ikeda; Michihisa Moriguchi; Takashi Hisai; Kenichi Yoshimura; Junji Furuse; Yasuaki Arai
Liver Cancer (2024) 13 (1): 99–112.
https://doi.org/10.1159/000531377
